CZ2015384A3 - Pevné formy Tenofovir alafenamidu - Google Patents

Pevné formy Tenofovir alafenamidu Download PDF

Info

Publication number: CZ2015384A3
Authority: CZ; Czechia
Prior art keywords: tenofovir alafenamide; acid; common; solid form; shows
Prior art date: 2015-06-05

Application number

CZ2015-384A

Other languages

Czech (cs)

English (en)

Inventor

Ondřej Dammer

Tereza Skalická

Lukáš Krejčík

Tomáš Pekárek

Luděk Ridvan

Original Assignee

Zentiva, K.S.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-05

Filing date

2015-06-05

Publication date

2016-12-14

2015-06-05 Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.

2015-06-05 Priority to CZ2015-384A priority Critical patent/CZ2015384A3/cs

2016-05-30 Priority to PCT/CZ2016/000059 priority patent/WO2016192692A1/fr

2016-12-14 Publication of CZ2015384A3 publication Critical patent/CZ2015384A3/cs

Links

239000007787 solid Substances 0.000 title claims abstract description 125
LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 title claims description 155
229960004946 tenofovir alafenamide Drugs 0.000 title claims description 155
150000007524 organic acids Chemical class 0.000 claims abstract description 15
150000007522 mineralic acids Chemical class 0.000 claims abstract description 10
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
208000031886 HIV Infections Diseases 0.000 claims abstract description 3
208000037357 HIV infectious disease Diseases 0.000 claims abstract description 3
239000003814 drug Substances 0.000 claims abstract description 3
208000002672 hepatitis B Diseases 0.000 claims abstract description 3
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims abstract description 3
239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 36
239000000843 powder Substances 0.000 claims description 30
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 24
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 22
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 22
LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 22
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 22
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 21
239000002904 solvent Substances 0.000 claims description 19
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 15
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 12
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 12
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 12
229940092714 benzenesulfonic acid Drugs 0.000 claims description 12
230000008020 evaporation Effects 0.000 claims description 12
238000001704 evaporation Methods 0.000 claims description 12
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 12
239000011976 maleic acid Substances 0.000 claims description 12
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 11
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 11
229960004050 aminobenzoic acid Drugs 0.000 claims description 11
229940074391 gallic acid Drugs 0.000 claims description 11
235000004515 gallic acid Nutrition 0.000 claims description 11
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 11
229960004889 salicylic acid Drugs 0.000 claims description 11
239000001384 succinic acid Substances 0.000 claims description 11
230000009477 glass transition Effects 0.000 claims description 8
235000002906 tartaric acid Nutrition 0.000 claims description 8
239000011975 tartaric acid Substances 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 7
150000002148 esters Chemical class 0.000 claims description 7
SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 claims description 4
150000001298 alcohols Chemical class 0.000 claims description 3
150000001408 amides Chemical class 0.000 claims description 2
150000002170 ethers Chemical class 0.000 claims description 2
150000002576 ketones Chemical class 0.000 claims description 2
150000002825 nitriles Chemical class 0.000 claims description 2
229960003560 tenofovir alafenamide fumarate Drugs 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 8
229960004556 tenofovir Drugs 0.000 abstract description 5
VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 abstract description 5
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 66
238000002329 infrared spectrum Methods 0.000 description 37
238000000113 differential scanning calorimetry Methods 0.000 description 33
230000008018 melting Effects 0.000 description 19
238000002844 melting Methods 0.000 description 19
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 14
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 14
238000000634 powder X-ray diffraction Methods 0.000 description 13
239000000047 product Substances 0.000 description 12
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 11
239000000126 substance Substances 0.000 description 8
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
238000001565 modulated differential scanning calorimetry Methods 0.000 description 7
210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 7
-1 pentyl formic acid ester Chemical class 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
239000012265 solid product Substances 0.000 description 7
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 5
238000000034 method Methods 0.000 description 5
229960001367 tartaric acid Drugs 0.000 description 5
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 4
229940048879 dl tartaric acid Drugs 0.000 description 4
239000011521 glass Substances 0.000 description 4
238000010438 heat treatment Methods 0.000 description 4
235000005985 organic acids Nutrition 0.000 description 4
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000013543 active substance Substances 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 2
238000009472 formulation Methods 0.000 description 2
238000005259 measurement Methods 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
239000012453 solvate Substances 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000006641 stabilisation Effects 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005160 1H NMR spectroscopy Methods 0.000 description 1
150000005416 4-aminobenzoic acids Chemical class 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229910016523 CuKa Inorganic materials 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
238000004566 IR spectroscopy Methods 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 1
229940123527 Nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
230000035508 accumulation Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
BAZMYXGARXYAEQ-UHFFFAOYSA-N alpha-ethyl valeric acid Chemical compound CCCC(CC)C(O)=O BAZMYXGARXYAEQ-UHFFFAOYSA-N 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
239000012159 carrier gas Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
ZCIGNRJZKPOIKD-CQXVEOKZSA-N cobicistat Chemical compound S1C(C(C)C)=NC(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](CC=2C=CC=CC=2)NC(=O)OCC=2SC=NC=2)CC=2C=CC=CC=2)=C1 ZCIGNRJZKPOIKD-CQXVEOKZSA-N 0.000 description 1
229960002402 cobicistat Drugs 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002447 crystallographic data Methods 0.000 description 1
229960005107 darunavir Drugs 0.000 description 1
CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
JUZYLCPPVHEVSV-LJQANCHMSA-N elvitegravir Chemical compound COC1=CC=2N([C@H](CO)C(C)C)C=C(C(O)=O)C(=O)C=2C=C1CC1=CC=CC(Cl)=C1F JUZYLCPPVHEVSV-LJQANCHMSA-N 0.000 description 1
229960003586 elvitegravir Drugs 0.000 description 1
229960000366 emtricitabine Drugs 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000004030 hiv protease inhibitor Substances 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
239000012535 impurity Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
150000003833 nucleoside derivatives Chemical class 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
102000054765 polymorphisms of proteins Human genes 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003138 primary alcohols Chemical class 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000004545 purin-9-yl group Chemical group N1=CN=C2N(C=NC2=C1)* 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
150000003870 salicylic acids Chemical class 0.000 description 1
150000003333 secondary alcohols Chemical class 0.000 description 1
SBIBMFFZSBJNJF-UHFFFAOYSA-N selenium;zinc Chemical compound [Se]=[Zn] SBIBMFFZSBJNJF-UHFFFAOYSA-N 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000003595 spectral effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
ZZIZZTHXZRDOFM-XFULWGLBSA-N tamsulosin hydrochloride Chemical compound [H+].[Cl-].CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 ZZIZZTHXZRDOFM-XFULWGLBSA-N 0.000 description 1
229960001355 tenofovir disoproxil Drugs 0.000 description 1
JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 1
150000003509 tertiary alcohols Chemical class 0.000 description 1
230000007704 transition Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Communicable Diseases (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CZ2015-384A 2015-06-05 2015-06-05 Pevné formy Tenofovir alafenamidu CZ2015384A3 (cs)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
CZ2015-384A CZ2015384A3 (cs)	2015-06-05	2015-06-05	Pevné formy Tenofovir alafenamidu
PCT/CZ2016/000059 WO2016192692A1 (fr)	2015-06-05	2016-05-30	Formes solides d'alafénamide de ténofovir

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CZ2015-384A CZ2015384A3 (cs)	2015-06-05	2015-06-05	Pevné formy Tenofovir alafenamidu

Publications (1)

Publication Number	Publication Date
CZ2015384A3 true CZ2015384A3 (cs)	2016-12-14

Family

ID=56119260

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CZ2015-384A CZ2015384A3 (cs)	2015-06-05	2015-06-05	Pevné formy Tenofovir alafenamidu

Country Status (2)

Country	Link
CZ (1)	CZ2015384A3 (fr)
WO (1)	WO2016192692A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2016277859B2 (en)	2015-06-17	2019-08-01	Gilead Sciences, Inc.	Co-crystals, salts and solid forms of tenofovir alafenamide
WO2018115046A1 (fr)	2016-12-23	2018-06-28	Sandoz Ag	Formes solides cristallines de ténofovir alafénamide
TW202510891A (zh)	2017-01-31	2025-03-16	美商基利科學股份有限公司	替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
CN107522743A (zh) *	2017-09-30	2017-12-29	深圳科兴生物工程有限公司	一种半富马酸替诺福韦艾拉酚胺工业化连续生产方法
WO2021165995A1 (fr)	2020-02-20	2021-08-26	Cipla Limited	Nouveaux sels et/ou co-cristaux de ténofovir alafénamide
US11667656B2 (en)	2021-01-27	2023-06-06	Apotex Inc.	Crystalline forms of Tenofovir alafenamide
KR20240109533A (ko) *	2023-01-04	2024-07-11	주식회사 종근당	테노포비르 알라페나미드 또는 이의 약제학적으로 허용가능한 염을 포함하는 안정성이 향상된 약제학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2682397B1 (fr)	2000-07-21	2017-04-19	Gilead Sciences, Inc.	Promédicaments d'analogues de nucléotides phosphonatés et procédés permettant de sélectionner et fabriquer ceux-ci
UA115311C2 (uk)	2011-08-16	2017-10-25	Гіліад Сайєнсіз, Інк.	Геміфумарат тенофовіру алафенаміду
IN2013MU01967A (fr) *	2013-06-07	2015-06-12	Cipla Ltd
WO2015040640A2 (fr) *	2013-09-20	2015-03-26	Laurus Labs Private Limited	Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
IN2014MU00118A (fr) *	2014-01-14	2015-08-28	Mylan Lab Ltd
CN105085571A (zh) *	2014-05-20	2015-11-25	四川海思科制药有限公司	替诺福韦艾拉酚胺复合物及其制备方法和用途

2015
- 2015-06-05 CZ CZ2015-384A patent/CZ2015384A3/cs unknown
2016
- 2016-05-30 WO PCT/CZ2016/000059 patent/WO2016192692A1/fr not_active Ceased

Also Published As

Publication number	Publication date
WO2016192692A1 (fr)	2016-12-08

Publication	Publication Date	Title
CZ2015384A3 (cs)	2016-12-14	Pevné formy Tenofovir alafenamidu
AU2016277859B2 (en)	2019-08-01	Co-crystals, salts and solid forms of tenofovir alafenamide
ES2727952T3 (es)	2019-10-21	Sal de adición de ácido de ibrutinib
EP3205653B1 (fr)	2020-11-25	Forme cristalline de bisulfate d'inhibiteur de jak et son procédé de préparation
AU2014239995A1 (en)	2015-09-10	Salt of omecamtiv mecarbil and process for preparing salt
EP3218351B1 (fr)	2019-06-19	Procédé de préparation, d'isolation et de purification de formes pharmaceutiquement applicables de ahu-377
CN104379582A (zh)	2015-02-25	包含达沙替尼和所选择的共晶体形成剂的多组分晶体
CN106715439A (zh)	2017-05-24	化合物
CN110650963A (zh)	2020-01-03	(S)-2-((2-((S)-4-(二氟甲基)-2-氧代噁唑烷-3-基)-5,6-二氢苯并[f]咪唑并[1,2-d][1,4]氧氮杂*-9-基)氨基)丙酰胺的多晶型物和固体形式及其制备方法
JP2025538506A (ja)	2025-11-28	がんの治療のための縮合ピリジンの固体形態
CZ2016276A3 (cs)	2017-11-22	Pevné formy volné báze ibrutinibu
TW201609717A (zh)	2016-03-16	Ｐｌｋ－４抑制劑之鹽和結晶形式
JP2016512518A (ja)	2016-04-28	ベムラフェニブ塩酸塩の固体形態
CZ201584A3 (cs)	2016-08-17	Sůl Ibrutinib sulfátu
CN110573163A (zh)	2019-12-13	抗病毒的膦酸酯类似物的盐及其制备方法
CA2932560A1 (fr)	2015-06-11	Formes cristallines de sels pharmaceutiquement acceptables de la n-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phtalazinamine et leurs utilisat ions
WO2014034626A1 (fr)	2014-03-06	CRISTAL DE N-[2-({2-[(2S)-2-CYANOPYRROLIDIN-1-YL]-2- OXOÉTHYL}AMINO)-2-MÉTHYLPROPYL]-2-MÉTHYLPYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXAMIDE
CZ201769A3 (cs)	2018-08-15	Pevné formy venetoclaxu
CZ2014708A3 (cs)	2016-04-27	Soli Bedaquilinu
JP2025511331A (ja)	2025-04-15	Ｍｃｉ－１アンタゴニストの非晶質及び結晶性形態
WO2017211325A1 (fr)	2017-12-14	Nouvelle forme cristalline de sel de ténofovir alafénamide, procédé de préparation et utilisation correspondante
CZ2015442A3 (cs)	2017-01-04	Ibrutinib hemisulfát
WO2020252047A1 (fr)	2020-12-17	Formes solides d'un inhibiteur de la kynurénine-3-monooxygénase
EP3781568A1 (fr)	2021-02-24	Forme de ponatinib
KR20230155499A (ko)	2023-11-10	다중-티로신 키나제 억제제의 결정질 염, 제조 방법, 및 이의 용도